- Home
- BUR vs GLUE Comparison
BUR vs GLUE Comparison
Compare BUR & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUR | GLUE |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BUR | GLUE |
|---|---|---|
| Price | $4.10 | $12.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.58 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $413,360,000.00 | $123,672,000.00 |
| Revenue This Year | $104.62 | N/A |
| Revenue Next Year | N/A | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $3.59 | $6.17 |
| 52 Week High | $13.07 | $25.77 |
Technical Indicators
Market Signals| Indicator | BUR | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 31.42 |
| Support Level | $4.13 | N/A |
| Resistance Level | $4.49 | $15.00 |
| Average True Range (ATR) | 0.16 | 0.76 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 22.89 | 5.63 |
Price Performance
Historical ComparisonAbout BUR Burford Capital Limited
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).